|
1
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Ascha MS, Hanouneh IA, Lopez R, et al: The
incidence and risk factors of hepatocellular carcinoma in patients
with nonalcoholic steatohepatitis. Hepatology. 51:1972–1978. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Severi T, van Malenstein H, Verslype C and
van Pelt JF: Tumor initiation and progression in hepatocellular
carcinoma: risk factors, classification, and therapeutic targets.
Acta Pharmacol Sin. 31:1409–1420. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu Y, Pan S, Liu L, et al: A genetic
variant in long non-coding RNA HULC contributes to risk of
HBV-related hepatocellular carcinoma in a Chinese population. PloS
One. 7:e351452012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kang TW, Yevsa T, Woller N, et al:
Senescence surveillance of pre-malignant hepatocytes limits liver
cancer development. Nature. 479:547–551. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kanwal F, Hoang T, Kramer JR, et al:
Increasing prevalence of HCC and cirrhosis in patients with chronic
hepatitis C virus infection. Gastroenterology. 140:1182–1188. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nguyen VT, Law MG and Dore GJ: Hepatitis
B-related hepatocellular carcinoma: epidemiological characteristics
and disease burden. J Viral Hepat. 16:453–463. 2009. View Article : Google Scholar
|
|
8
|
Nejak-Bowen KN, Thompson MD, Singh S, et
al: Accelerated liver regeneration and hepatocarcinogenesis in mice
overexpressing serine-45 mutant beta-catenin. Hepatology.
51:1603–1613. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng CW, Chow AK, Pang R, et al: PIN1
inhibits apoptosis in hepatocellular carcinoma through modulation
of the antiapoptotic function of survivin. Am J Pathol.
182:765–775. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abrahamsen H, O’Neill AK, Kannan N, et al:
Peptidyl-prolyl isomerase Pin1 controls down-regulation of
conventional protein kinase C isozymes. J Biol Chem.
287:13262–13278. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bao L, Kimzey A, Sauter G, et al:
Prevalent overexpression of prolyl isomerase Pin1 in human cancers.
Am J Pathol. 164:1727–1737. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aluise CD, Rose K, Boiani M, et al:
Peptidyl-prolyl cis/trans-isomerase A1 (Pin1) is a target for
modification by lipid electrophiles. Chem Res Toxicol. 26:270–279.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tabarés-Seisdedos R and Rubenstein JL:
Inverse cancer comorbidity: a serendipitous opportunity to gain
insight into CNS disorders. Nat Rev Neurosci. 14:293–304.
2013.PubMed/NCBI
|
|
14
|
Lu KP and Zhou XZ: The prolyl isomerase
PIN1: a pivotal new twist in phosphorylation signalling and
disease. Nat Rev Mol Cell Biol. 8:904–916. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Teng BL, Hacker KE, Chen S, et al: Tumor
suppressive activity of prolyl isomerase Pin1 in renal cell
carcinoma. Mol Oncol. 5:465–474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pang RW, Lee TK, Man K, et al: PIN1
expression contributes to hepatic carcinogenesis. J Pathol.
210:19–25. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maher MT, Flozak AS, Stocker AM, et al:
Activity of the beta-catenin phosphodestruction complex at
cell-cell contacts is enhanced by cadherin-based adhesion. J Cell
Biol. 186:219–228. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schmalhofer O, Brabletz S and Brabletz T:
E-cadherin, beta-catenin, and ZEB1 in malignant progression of
cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012.
|
|
20
|
Stein TJ, Jochem A, Holmes KE and Sandgren
EP: Effect of mutant β-catenin on liver growth homeostasis and
hepatocarcinogenesis in transgenic mice. Liver Int. 31:303–312.
2011.
|
|
21
|
Zimmerman ZF, Moon RT and Chien AJ:
Targeting Wnt pathways in disease. Cold Spring Harb Perspect Biol.
Nov 1–2012.(Epub ahead of print).
|
|
22
|
Herr P, Hausmann G and Basler K: WNT
secretion and signalling in human disease. Trends Mol Med.
18:483–493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hayakawa Y, Hirata Y, Nakagawa H, et al:
Apoptosis signal-regulating kinase 1 and cyclin D1 compose a
positive feedback loop contributing to tumor growth in gastric
cancer. Proc Natl Acad Sci USA. 108:780–785. 2011. View Article : Google Scholar
|
|
24
|
Santarius T, Shipley J, Brewer D, et al: A
census of amplified and overexpressed human cancer genes. Nat Rev
Cancer. 10:59–64. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vaites LP, Lee EK, Lian Z, et al: The Fbx4
tumor suppressor regulates cyclin D1 accumulation and prevents
neoplastic transformation. Mol Cell Biol. 31:4513–4523. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang C, Lisanti MP and Liao DJ: Reviewing
once more the c-myc and Ras collaboration: converging at the cyclin
D1-CDK4 complex and challenging basic concepts of cancer biology.
Cell Cycle. 10:57–67. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Parekh P, Motiwale L, Naik N and Rao KV:
Downregulation of cyclin D1 is associated with decreased levels of
p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of
resveratrol in liver cancer cells. Exp Toxicol Pathol. 63:167–173.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang S and He X: The role of microRNAs in
liver cancer progression. Br J Cancer. 104:235–240. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pang RW and Poon RT: Diagnosis: Novel
prognostic biomarkers in hepatocellular carcinoma. Nat Rev
Gastroenterol Hepatol. 9:691–692. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu GG and Etzkorn FA: Pin1 as an
anticancer drug target. Drug News Perspect. 22:399–407. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brembeck FH, Rosário M and Birchmeier W:
Balancing cell adhesion and Wnt signaling, the key role of
beta-catenin. Curr Opin Genet Dev. 16:51–59. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shen M, Stukenberg PT, Kirschner MW and Lu
KP: The essential mitotic peptidyl-prolyl isomerase Pin1 binds and
regulates mitosis-specific phosphoproteins. Genes Dev. 12:706–720.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takahashi K, Uchida C, Shin RW, et al:
Prolyl isomerase, Pin1: new findings of post-translational
modifications and physiological substrates in cancer, asthma and
Alzheimer’s disease. Cell Mol Life Sci. 65:359–375. 2008.PubMed/NCBI
|
|
34
|
Inagawa S, Itabashi M, Adachi S, et al:
Expression and prognostic roles of beta-catenin in hepatocellular
carcinoma: correlation with tumor progression and postoperative
survival. Clin Cancer Res. 8:450–456. 2002.PubMed/NCBI
|
|
35
|
David CJ and Manley JL: Alternative
pre-mRNA splicing regulation in cancer: pathways and programs
unhinged. Genes Dev. 24:2343–2364. 2010. View Article : Google Scholar : PubMed/NCBI
|
